Mazdutide
Research profile · How we handle evidence
Mazdutide is a dual GLP-1 receptor and glucagon receptor agonist that’s been studied for weight management and type 2 diabetes. It’s an investigational research entry here (not a supplement claim).
Evidence Score
Moderate confidence
Category
Therapeutic area
Standard Dose
Once weekly
Half-life
Plasma elimination
Route
Subcutaneous
Safety Tier
Monitor closely
Overview
Mazdutide is designed to hit two targets involved in glucose control and appetite signaling. GLP-1 receptor activity is commonly linked with reduced appetite and slower gastric emptying, while glucagon receptor activity may contribute to additional metabolic effects. Human evidence (mostly early-to-mid clinical phases) suggests efficacy signals, but the details depend on the dose and the study population. If you’re comparing options, treat this as educational context and avoid using it as a substitute for clinician guidance—especially because GLP-1–class compounds are often associated with gastrointestinal side effects.
Mechanism of Action
Mazdutide is designed to hit two targets involved in glucose control and appetite signaling. GLP-1 receptor activity is commonly linked with reduced appetite and slower gastric emptying, while glucagon receptor activity may contribute to additional metabolic effects. Human evidence (mostly early-to-mid clinical phases) suggests efficacy signals, but the details depend on the dose and the study population. If you’re comparing options, treat this as educational context and avoid using it as a substitute for clinician guidance—especially because GLP-1–class compounds are often associated with gastrointestinal side effects.
pH & Mixing
Peptides reconstituted at very different pH levels can destabilize when combined in the same syringe, which lowers how much of the peptide your body actually absorbs. If you're unsure whether two peptides are close enough in pH, reconstitute and inject them separately.
A dedicated compatibility check between two specific peptides is coming to the Compare tool. This section covers this peptide's pH only.
Benefits
- Weight loss
- Improved glycemic control
- Cardiovascular benefits
- Dual mechanism
Side Effects
- Gastrointestinal side effects (for example nausea, vomiting, diarrhea)
- Headache
- Injection-site discomfort
Contraindications
- Pregnant or breastfeeding women
- Personal or family history of medullary thyroid carcinoma or MEN2 (when applicable to your clinician’s guidance)
- Known hypersensitivity to the peptide components
Structure & Sequence
Verified structure
Mazdutide
Illustration uses the catalog amino acid sequence because no exact external registry match was confirmed.
- Amino Acid Sequence
- His-Aib-Gln-Gly-Thr-Phe-Thr-Ser-Asp-Tyr-Ser-Lys-Tyr-Leu-Asp-Glu-Lys-Lys-Ala-Lys-(AEEA-AEEA-gGlu-Eicosanedioic acid)-Glu-Phe-Val-Glu-Trp-Leu-Leu-Glu-Gly-Gly-Pro-Ser-Ser-Gly-NH2
- Molecular Weight
- 4,563.06 Da
- Chemical Formula
- C210H322N46O67
- CAS Number
- N/A
- Reconstituted pH
- 4.7
Stack & Route Context
Stacks with
No entries listed.
Administration
Subcutaneous
Research Status
Phase 2 clinical trials in China
Approval Status
Phase2
Sports Legal
Permitted
References
- 1View source
A phase 2 randomised controlled trial of mazdutide in Chinese adults with overweight or obesity
2023
- 2View source
Mazdutide versus placebo in Chinese adults with type 2 diabetes (clinical trial results)
2025
This profile summarizes research literature for education only. It is not medical advice, and it does not diagnose, treat, or recommend a dose. Consult a qualified professional before changing a protocol.